MagicTouch PTA designed with proprietary Nanolute Technology is intended for percutaneous transluminal angioplasty of de-novo, stenotic and in-stent restenotic lesions in Superficial femoral (SFA), popliteal, Below The Knee (BTK) and iliac arteries.

MagicTouch PTA - Sirolimus Coated Balloon for Peripheral artery disease
01
Touch to Thrive in Peripheral Health

Aimed at revascularizing SFA, BTK, Popliteal & Iliac arteries, focusing on prevention on re-narrowing in peripheral arterial disease, with credits to the safety and efficacy of Sirolimus Coating Tech, ensuring best-in-class patency.

  • US FDA IDE approved in BTK & SFA Indications

  • The most clinically studied SCB in PAD

  • CE Approved

02

Key Indications:
  • In Stent Restenosis
  • Stenotic Lesions
  • De-Novo Lesions
  • CLTI

03

Technology

Nanolute is an advanced drug delivery technology designed to enhance the efficiency of drug administration and retention, enabling sustained delivery from non-implantable devices. Nanolute is capable of delivering drugs effectively, regardless of whether their lipophilicity is poor or high.

Nanolute - Sirolimus Coated Balloon- MagicTouch PTA

Unique coating technology

Magic Touch is developed with Nanolute Technology which possesses unique circumferential coating technology that facilitates homogeneous drug distribution to target lesions
COATING Circumferential Coating is performed under Low Pressure inflation leading to 100% surface area coating

REFOLDING
3 to 6 Folds

INFLATION Homogeneous Drug Delivery due to Circumferential Coating
04
Assuring Safety by delivering Sirolimus

TECHNOLOGY
An innovative proprietary Nanolute technology providing better bioavailability of SIROLIMUS

DRUG
Sirolimus: A drug with proven safety profile

COATING
Unique coating technology leads to 100% balloon surface coating

CARRIER
A biocompatible phospholipid drug carrier improving the adhesion property of Sirolimus

05

Documentation
Get in touch
to know more
BOOK A CALL
with our sales rep